These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 27186634)

  • 1. Fixed-dose combinations of drugs versus single-drug formulations for treating pulmonary tuberculosis.
    Gallardo CR; Rigau Comas D; Valderrama Rodríguez A; Roqué i Figuls M; Parker LA; Caylà J; Bonfill Cosp X
    Cochrane Database Syst Rev; 2016 May; 2016(5):CD009913. PubMed ID: 27186634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Shortened treatment regimens versus the standard regimen for drug-sensitive pulmonary tuberculosis.
    Grace AG; Mittal A; Jain S; Tripathy JP; Satyanarayana S; Tharyan P; Kirubakaran R
    Cochrane Database Syst Rev; 2019 Dec; 12(12):CD012918. PubMed ID: 31828771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB.
    Sharma SK; Sharma A; Kadhiravan T; Tharyan P
    Cochrane Database Syst Rev; 2013 Jul; 2013(7):CD007545. PubMed ID: 23828580
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Six-month therapy for abdominal tuberculosis.
    Jullien S; Jain S; Ryan H; Ahuja V
    Cochrane Database Syst Rev; 2016 Nov; 11(11):CD012163. PubMed ID: 27801499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB.
    Sharma SK; Sharma A; Kadhiravan T; Tharyan P
    Evid Based Child Health; 2014 Mar; 9(1):169-294. PubMed ID: 25404581
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Linezolid for drug-resistant pulmonary tuberculosis.
    Singh B; Cocker D; Ryan H; Sloan DJ
    Cochrane Database Syst Rev; 2019 Mar; 3(3):CD012836. PubMed ID: 30893466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fluoroquinolones for treating tuberculosis (presumed drug-sensitive).
    Ziganshina LE; Titarenko AF; Davies GR
    Cochrane Database Syst Rev; 2013 Jun; 2013(6):CD004795. PubMed ID: 23744519
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intermittent versus daily therapy for treating tuberculosis in children.
    Bose A; Kalita S; Rose W; Tharyan P
    Cochrane Database Syst Rev; 2014 Jan; 2014(1):CD007953. PubMed ID: 24470141
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Directly observed therapy for treating tuberculosis.
    Karumbi J; Garner P
    Cochrane Database Syst Rev; 2015 May; 2015(5):CD003343. PubMed ID: 26022367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nutritional supplements for people being treated for active tuberculosis.
    Grobler L; Nagpal S; Sudarsanam TD; Sinclair D
    Cochrane Database Syst Rev; 2016 Jun; 2016(6):CD006086. PubMed ID: 27355911
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Primaquine alternative dosing schedules for preventing malaria relapse in people with Plasmodium vivax.
    Milligan R; Daher A; Villanueva G; Bergman H; Graves PM
    Cochrane Database Syst Rev; 2020 Aug; 8():CD012656. PubMed ID: 32816320
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efavirenz or nevirapine in three-drug combination therapy with two nucleoside or nucleotide-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals.
    Mbuagbaw L; Mursleen S; Irlam JH; Spaulding AB; Rutherford GW; Siegfried N
    Cochrane Database Syst Rev; 2016 Dec; 12(12):CD004246. PubMed ID: 27943261
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19.
    Singh B; Ryan H; Kredo T; Chaplin M; Fletcher T
    Cochrane Database Syst Rev; 2021 Feb; 2(2):CD013587. PubMed ID: 33624299
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Corticosteroids for tuberculous pleurisy.
    Ryan H; Yoo J; Darsini P
    Cochrane Database Syst Rev; 2017 Mar; 3(3):CD001876. PubMed ID: 28290161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of the diagnostic test Xpert MTB/RIF on patient outcomes for tuberculosis.
    Haraka F; Kakolwa M; Schumacher SG; Nathavitharana RR; Denkinger CM; Gagneux S; Reither K; Ross A
    Cochrane Database Syst Rev; 2021 May; 5(5):CD012972. PubMed ID: 34097769
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anthelmintic drugs for treating ascariasis.
    Conterno LO; Turchi MD; Corrêa I; Monteiro de Barros Almeida RA
    Cochrane Database Syst Rev; 2020 Apr; 4(4):CD010599. PubMed ID: 32289194
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fixed-dose combination therapy for the prevention of cardiovascular disease.
    de Cates AN; Farr MR; Wright N; Jarvis MC; Rees K; Ebrahim S; Huffman MD
    Cochrane Database Syst Rev; 2014 Apr; 4(4):CD009868. PubMed ID: 24737108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
    API Consensus Expert Committee
    J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular diseases.
    Bahiru E; de Cates AN; Farr MR; Jarvis MC; Palla M; Rees K; Ebrahim S; Huffman MD
    Cochrane Database Syst Rev; 2017 Mar; 3(3):CD009868. PubMed ID: 28263370
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.